EG BioMed

【Great partnerships always start with great conversations！】
We’ve spent some amazing quality time with the Numia Health team lately, bouncing ideas off each other and visionary planning. Today, we’re super excited to share a major milestone EG BioMed is officially joining hands with Numia Health to bring our cancer blood testing services to Canada! 🇨🇦✨

When passionate minds sit around the table with a shared vision, the goal becomes simple making advanced, cross-border health tech more accessible and seamless for everyone.
This is just the beginning of our journey in North America. Stay tuned, exciting updates are right around the corner!

A special thank you to Justin Kao, Adrián Sahagún, and Fernando Pintado for helping initiate and support this collaboration and for sharing our commitment to making precision healthcare more accessible.

We would like to express our deepest appreciation to all participating partners and guests for making the past four days a tremendous success.
During these insightful four days, the EG BioMed team was delighted to connect with industry peers and attendees. The engaging discussions and exchange of perspectives allowed us to showcase our professional expertise while highlighting the growing collective emphasis on healthcare and biomedical innovation.

Our sincere thanks go out to everyone who made the journey to visit us. EG BioMed will continue to adhere to the highest professional standards, providing superior products and services. We look forward to continuing these valuable dialogues and further strengthening our collaborative relationships in H2!

📣 7/17（五）下午 2:00｜南港展覽館一館 北醫大舞臺
一起解鎖身體的甲基化密碼，探索 AI × 癌症早期風險評估！
🎁 現場有獎徵答，歡迎大家一起參加！

📢 誠摯邀請您蒞臨 2026 亞洲生技大展！
EG BioMed 將於 2026 亞洲生技大展 (Bio Asia–Taiwan Exhibition 2026) 展出最新 OkaiDx 癌症早期檢測平台，展示整合 AI 癌症風險評估、液態切片（Liquid Biopsy） 與 早期癌症檢測 的創新解決方案。
歡迎蒞臨 美國館華盛頓州區 M709，與我們交流最新技術、臨床應用及國際合作機會，共同推動精準醫療與癌症早期偵測的未來。
📍 展位：美國館 華盛頓州區 M709
📅 日期：2026 年 7 月 16–19 日
🕙 時間：10:00–18:00（7/19 至 17:00）
📍 地點：台北南港展覽館一館 4F
期待與您相見！

Meet EG BioMed at BIO Asia–Taiwan 2026!
Learn how our nationwide Telehealth Platform delivers an end-to-end cancer testing ecosystem—from telemedicine and mobile phlebotomy to CLIA/CAP-certified laboratory testing and digital reporting. Operating across 47 U.S. states, we're expanding access to precision healthcare.
Visit us at the U.S. Pavilion Booth M709, July 16–19!

【An Inspiring Week in San Diego! 】

What an incredible experience at AACR 2026! EG BioMed is heading home energized by the groundbreaking science and meaningful connections we made this year.

For us, this week was about more than just data—it was about the power of collaboration. Every conversation we had reinforced our belief that cross-disciplinary partnerships are the true engine behind the next generation of non-invasive cancer detection.

A special thank you to：
💪Our visionary leaders, Dr. Ruo-kai Lin and Dr. Chin-sheng Hung, for their expertise and for presenting our latest findings on circulating DNA methylation to the global stage.
💪Our partners at YD Bio for their unwavering support and shared commitment to innovation.
💪Everyone who stopped by our poster to discuss the future of liquid biopsy.

We are actively looking to build new partnerships with academic, clinical, and industry leaders worldwide. Let’s work together to bring impactful solutions to patients. Feel free to DM us or reach out via our website!

💜 Thank You, PanCAN PurpleStride Seattle 2026 💜
We are grateful to have been part of PanCAN PurpleStride on April 25 in Seattle, and honored that EG BioMed had the opportunity to participate as a sponsor.

This meaningful event brought communities together to raise awareness, support patients and families, and move closer to a future free from pancreatic cancer.

At our booth, we were glad to connect with participants and share information about pancreatic and gastrointestinal cancer, contributing to greater awareness and education—especially for those at higher risk.

We truly appreciate the opportunity to stand alongside this incredible community and support efforts toward better outcomes for patients.

National DNA Day

From the discovery of DNA to today’s breakthroughs in genomic medicine, science continues to reshape how we understand and detect disease.

One of the most impactful advances is cell-free DNA (cfDNA) in plasma—a powerful, non-invasive approach that enables：
🔬 Early cancer risk assessment
🔬 Precision diagnostics
🔬 Better-informed clinical decisions

At EG BioMed, we are leveraging cfDNA technology to advance early detection of gastrointestinal cancers, helping identify risks earlier and improve patient outcomes.
From DNA discovery → to cfDNA innovation → to earlier detection.
Do you know your cancer risk?
👉 Learn more: https://lnkd.in/gJKv5jvQ